{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:37:43Z","timestamp":1790739463793,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"A Breath of Hope Lung Cancer Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1038\/s41417-018-0074-6","type":"journal-article","created":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T23:51:04Z","timestamp":1546905064000},"page":"411-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["JAK\/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models"],"prefix":"10.1038","volume":"26","author":[{"given":"Manish R.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9337-3417","authenticated-orcid":false,"given":"Alexander","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2597-1503","authenticated-orcid":false,"given":"Kareem","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,9]]},"reference":[{"key":"74_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.trsl.2012.12.010","volume":"161","author":"MR Patel","year":"2013","unstructured":"Patel MR, Kratzke RA. Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res. 2013;161:355\u201364.","journal-title":"Transl Res"},{"key":"74_CR2","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.1158\/0008-5472.CAN-09-1013","volume":"69","author":"CL Willmon","year":"2009","unstructured":"Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, et al. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res. 2009;69:7713\u201320.","journal-title":"Cancer Res"},{"key":"74_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.virol.2012.11.014","volume":"436","author":"M Moerdyk-Schauwecker","year":"2013","unstructured":"Moerdyk-Schauwecker M, Shah NR, Murphy AM, Hastie E, Mukherjee P, Grdzelishvili VZ. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology. 2013;436:221\u201334.","journal-title":"Virology"},{"key":"74_CR4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/cgt.2013.55","volume":"20","author":"D Escobar-Zarate","year":"2013","unstructured":"Escobar-Zarate D, Liu YP, Suksanpaisan L, Russell SJ, Peng KW. Overcoming cancer cell resistance to VSV oncolysis with JAK1\/2 inhibitors. Cancer Gene Ther. 2013;20:582\u20139.","journal-title":"Cancer Gene Ther"},{"key":"74_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/hum.2009.088","volume":"21","author":"V Saloura","year":"2010","unstructured":"Saloura V, Wang LC, Fridlender ZG, Sun J, Cheng G, Kapoor V, et al. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther. 2010;21:51\u201364.","journal-title":"Hum Gene Ther"},{"key":"74_CR6","doi-asserted-by":"crossref","first-page":"33165","DOI":"10.18632\/oncotarget.5320","volume":"6","author":"MR Patel","year":"2015","unstructured":"Patel MR, Jacobson BA, Ji Y, Drees J, Tang S, Xiong K, et al. Vesicular stomatitis virus expressing interferon-beta is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. Oncotarget. 2015;6:33165\u201377.","journal-title":"Oncotarget"},{"key":"74_CR7","doi-asserted-by":"publisher","first-page":"16021","DOI":"10.1038\/mto.2016.21","volume":"3","author":"C Dold","year":"2016","unstructured":"Dold C, Rodriguez Urbiola C, Wollmann G, Egerer L, Muik A, Bellmann L, et al. Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy. Mol Ther Oncolytics. 2016;3:16021.","journal-title":"Mol Ther Oncolytics"},{"key":"74_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.virol.2015.08.003","volume":"485","author":"M Cataldi","year":"2015","unstructured":"Cataldi M, Shah NR, Felt SA, Grdzelishvili VZ. Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1. Virology. 2015;485:340\u201354.","journal-title":"Virology"},{"key":"74_CR9","doi-asserted-by":"publisher","first-page":"61601","DOI":"10.18632\/oncotarget.11202","volume":"7","author":"E Hastie","year":"2016","unstructured":"Hastie E, Cataldi M, Moerdyk-Schauwecker MJ, Felt SA, Steuerwald N, Grdzelishvili VZ. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. Oncotarget. 2016;7:61601\u201318.","journal-title":"Oncotarget"},{"key":"74_CR10","doi-asserted-by":"crossref","unstructured":"Hierholzer JC, Killington RA. Virus isolation and quantification. In: Mahy BWJ, Kangro HO, editors. Virology methods manual. San Diego: Academic Press Limited; 1996. p 25\u201346. .","DOI":"10.1016\/B978-012465330-6\/50003-8"},{"key":"74_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","volume":"5","author":"MA Ramakrishnan","year":"2016","unstructured":"Ramakrishnan MA. Determination of 50% endpoint titer using a simple formula. World J Virol. 2016;5:85\u20136.","journal-title":"World J Virol"},{"key":"74_CR12","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1158\/1078-0432.CCR-18-0267","volume":"24","author":"M Saigi","year":"2018","unstructured":"Saigi M, Alburquerque-Bejar JJ, Mc Leer-Florin A, Pereira C, Pros E, Romero OA, et al. MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer. Clin Cancer Res. 2018;24:4579\u201387.","journal-title":"Clin Cancer Res"},{"key":"74_CR13","doi-asserted-by":"publisher","first-page":"71249","DOI":"10.18632\/oncotarget.19531","volume":"8","author":"RFV Medrano","year":"2017","unstructured":"Medrano RFV, Hunger A, Mendonca SA, Barbuto JAM, Strauss BE. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget. 2017;8:71249\u201384.","journal-title":"Oncotarget"},{"key":"74_CR14","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1073\/pnas.1712452115","volume":"115","author":"BC Betts","year":"2018","unstructured":"Betts BC, Bastian D, Iamsawat S, Nguyen H, Heinrichs JL, Wu Y, et al. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci USA. 2018;115:1582\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"74_CR15","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1158\/0008-5472.CAN-16-2586","volume":"77","author":"L Borriello","year":"2017","unstructured":"Borriello L, Nakata R, Sheard MA, Fernandez GE, Sposto R, Malvar J, et al. Cancer-associated fibroblasts share characteristics and protumorigenic activity with mesenchymal stromal cells. Cancer Res. 2017;77:5142\u201357.","journal-title":"Cancer Res"},{"key":"74_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood-2016-09-742049","volume":"129","author":"A Tarafdar","year":"2017","unstructured":"Tarafdar A, Hopcroft LE, Gallipoli P, Pellicano F, Cassels J, Hair A, et al. CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood. 2017;129:199\u2013208.","journal-title":"Blood"},{"key":"74_CR17","doi-asserted-by":"publisher","first-page":"e1291106","DOI":"10.1080\/2162402X.2017.1291106","volume":"6","author":"C Lu","year":"2017","unstructured":"Lu C, Talukder A, Savage NM, Singh N, Liu K. JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology. 2017;6:e1291106.","journal-title":"Oncoimmunology"},{"key":"74_CR18","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167:1540\u201354 e12.","journal-title":"Cell"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0074-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0074-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0074-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:10:10Z","timestamp":1684617010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-018-0074-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,9]]},"references-count":18,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["74"],"URL":"https:\/\/doi.org\/10.1038\/s41417-018-0074-6","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,9]]},"assertion":[{"value":"15 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MRP is currently site principal investigator of a phase I study of VSV-IFN\u03b2-NIS sponsored by the manufacturer, Vyriad, without any financial compensation. The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}